Clinical Trial

Haemoglobin And Vancomycin Pharmacokinetics in the Cerebrospinal Fluid Following Subarachnoid Haemorrhage

Study acronym: HAPTO
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
The HAPTO study will recruit adult patients with aSAH due to a burst aneurysm. These patients must be scheduled to have their aneurysm treated surgically to prevent further bleeds, and need an external ventricular drain for clinical reasons (to drain fluid and relieve pressure on the brain). At the end of their surgery for their aneurysm, a further drain will be left at the site of the surgery (which is in the basal cisterns) and they will additionally have a drain sited in their lumbar spine. Vancomycin will be given through these drains. Additionally, these drains will allow the fluid in the brain to be collected to measure how haemoglobin levels and vancomycin levels differ between compartments and change over time. Patients will participate in the study over a period from recruitment at three days after aSAH to a maximum of ten days after aSAH. The data will be analysed to determine the relationship in haemoglobin concentrations between different areas of the brain and spine after aSAH, and how vancomycin distribution is related to its route of administration.
Trial Details
NCT Number NCT06373640
Lead Sponsor University Hospital Southampton NHS Foundation Trust
Conditions Subarachnoid Hemorrhage
Enrollment 14 participants
Start Date 2024-11
Primary Completion 2027-03 (estimated)
Study Completion 2028-01 (estimated)
Updated on ClinicalTrials.gov 2024-04-18